Undisclosed MRGPRX2 inhibitor / Arcus Biosciences - LARVOL DELTA

Emerging I&I Portfolio (Arcus Biosciences Press Release) - "Arcus expects to advance its first inflammation program, a potential best-in-class oral MRGPRX2 antagonist for atopic dermatitis and chronic spontaneous urticaria, into clinical development in 2026....Arcus also expects to advance an oral small-molecule TNF inhibitor, a potential treatment for rheumatoid arthritis, psoriasis and inflammatory bowel disease, into the clinic in late 2026 or early 2027."

New trial • Atopic Dermatitis • Chronic Spontaneous Urticaria • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis

Small-Molecule Inflammation & Immunology Programs (Businesswire) - "Arcus expects to advance its lead inflammation program, a potential best-in-class oral MRGPRX2 antagonist for atopic dermatitis and chronic spontaneous urticaria, into clinical development in 2026....Arcus also expects to advance an oral small-molecule TNF inhibitor, a potential treatment for rheumatoid arthritis, psoriasis and inflammatory bowel disease (such as ulcerative colitis), into the clinic in late 2026 or early 2027."

New trial • Atopic Dermatitis • Chronic Spontaneous Urticaria • Psoriasis • Rheumatoid Arthritis • Ulcerative Colitis

Arcus Provides Update on...Emerging Inflammation and Immunology Portfolio (Arcus Biosciences Press Release) - "Arcus expects to advance two potentially best-in-class small molecule inhibitors into the clinic in the timeframes noted below: 2026: MRGPRX2, a potential treatment for atopic dermatitis and chronic spontaneous urticaria; and Late 2026 - early 2027: TNF, a potential treatment for rheumatoid arthritis, psoriasis and inflammatory bowel disease (such as ulcerative colitis)."

New trial • Atopic Dermatitis • Chronic Spontaneous Urticaria • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis • Ulcerative Colitis

Arcus expects to select development candidates for at least three of these programs within the next 12 months (Businesswire) - "The first of these, a small molecule directed against MRGPRX2, is expected to enter the clinic in 2026."

New trial • Pipeline update • Atopic Dermatitis • Chronic Spontaneous Urticaria

Arcus..discovery and preclinical programs disclosed today provide multiple opportunities to advance into the clinic in 2026. (Arcus Biosciences Press Release) - "Potential new drug candidates include: MRGPRX2 small-molecule inhibitor, a potential treatment for atopic dermatitis and chronic spontaneous urticaria; TNF-a (TNFR1) small-molecule inhibitor, a potential treatment for rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (such as ulcerative colitis); CCR6 small-molecule inhibitor, a potential treatment for psoriasis; CD89 monoclonal antibody, a potential treatment for RA; CD40L small-molecule inhibitor, a potential treatment for multiple sclerosis and systemic lupus erythematosus"

New molecule • Atopic Dermatitis • Chronic Spontaneous Urticaria • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Systemic Lupus Erythematosus • Ulcerative Colitis